Rx Marketplace Quarterly: Q3 2019 Pharmaceutical and Life Science

Start adding items to your reading lists:
or
Save this item to:
This item has been saved to your reading list.

In this issue of Rx Marketplace you will find an overview of recent capital market activity, final and proposed GILTI regulations, recent SEC comment letter trends, and updates to our on-line US GAAP Issues and Solutions for Pharmaceuticals and Life Sciences Companies Guide (PLS Guide).

In our spotlight section, we feature PwC’s Health Research Institute group, which supports executive decision makers by providing new intelligence and analysis on trends affecting health industries.

Updated SEC comment letter trends 

Our analysis of SEC comment letters identifies the frequency of topical areas addressed by the SEC staff and how their focus has evolved over time. We have updated the rankings and topics to include those comment letters issued to Health Industries companies through June 30, 2019.

Spotlight on PwC's Health Research Institute (HRI)

PwC’s HRI was established in 2004 and supports executive decision makers by providing new intelligence and analysis on trends affecting health industries. HRI publishes ongoing coverage and analysis of new rules, regulations, and policy changes, such as changes to Medicare reimbursement for CAR-T therapies, and new digital health approval pathways at the FDA. Refer to the Top regulatory center news for further information and published articles.

Contact us

Laura Robinette

US Pharmaceutical & Life Sciences Assurance Leader, PwC US

Follow us